KR102596598B1 - 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체 - Google Patents

사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체 Download PDF

Info

Publication number
KR102596598B1
KR102596598B1 KR1020207033931A KR20207033931A KR102596598B1 KR 102596598 B1 KR102596598 B1 KR 102596598B1 KR 1020207033931 A KR1020207033931 A KR 1020207033931A KR 20207033931 A KR20207033931 A KR 20207033931A KR 102596598 B1 KR102596598 B1 KR 102596598B1
Authority
KR
South Korea
Prior art keywords
alkyl
fluoroalkyl
optionally substituted
formula
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207033931A
Other languages
English (en)
Korean (ko)
Other versions
KR20210002642A (ko
Inventor
핑 천
수진 초-슐츠
주디스 게일 딜
개리 마이클 갈레고
메란 잘레이
로버트 스티븐 카니아
사지브 크리쉬난 나이르
사차 닌코빅
수비 툴라 마르주카 오르
신시아 루이스 팔머
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Priority to KR1020237036862A priority Critical patent/KR102661053B1/ko
Publication of KR20210002642A publication Critical patent/KR20210002642A/ko
Application granted granted Critical
Publication of KR102596598B1 publication Critical patent/KR102596598B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
KR1020207033931A 2018-04-26 2019-04-22 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체 Active KR102596598B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237036862A KR102661053B1 (ko) 2018-04-26 2019-04-22 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862663096P 2018-04-26 2018-04-26
US62/663,096 2018-04-26
US201862750454P 2018-10-25 2018-10-25
US62/750,454 2018-10-25
US201962826609P 2019-03-29 2019-03-29
US62/826,609 2019-03-29
PCT/IB2019/053314 WO2019207463A1 (en) 2018-04-26 2019-04-22 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036862A Division KR102661053B1 (ko) 2018-04-26 2019-04-22 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체

Publications (2)

Publication Number Publication Date
KR20210002642A KR20210002642A (ko) 2021-01-08
KR102596598B1 true KR102596598B1 (ko) 2023-11-03

Family

ID=66676856

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207033931A Active KR102596598B1 (ko) 2018-04-26 2019-04-22 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체
KR1020237036862A Active KR102661053B1 (ko) 2018-04-26 2019-04-22 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237036862A Active KR102661053B1 (ko) 2018-04-26 2019-04-22 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체

Country Status (40)

Country Link
US (3) US10766884B2 (cg-RX-API-DMAC10.html)
EP (1) EP3784664B1 (cg-RX-API-DMAC10.html)
JP (2) JP7089061B2 (cg-RX-API-DMAC10.html)
KR (2) KR102596598B1 (cg-RX-API-DMAC10.html)
CN (2) CN118286225A (cg-RX-API-DMAC10.html)
AU (1) AU2019259653B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020021689B1 (cg-RX-API-DMAC10.html)
CA (1) CA3098283C (cg-RX-API-DMAC10.html)
CL (1) CL2020002748A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020013149A2 (cg-RX-API-DMAC10.html)
CR (1) CR20200503A (cg-RX-API-DMAC10.html)
CU (1) CU20200070A7 (cg-RX-API-DMAC10.html)
DK (1) DK3784664T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2020000191A (cg-RX-API-DMAC10.html)
EC (1) ECSP20067394A (cg-RX-API-DMAC10.html)
ES (1) ES3021205T3 (cg-RX-API-DMAC10.html)
FI (1) FI3784664T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20227433B (cg-RX-API-DMAC10.html)
HR (1) HRP20250254T1 (cg-RX-API-DMAC10.html)
HU (1) HUE070823T2 (cg-RX-API-DMAC10.html)
IL (1) IL278075B2 (cg-RX-API-DMAC10.html)
LT (1) LT3784664T (cg-RX-API-DMAC10.html)
MA (1) MA52360B1 (cg-RX-API-DMAC10.html)
MD (1) MD3784664T2 (cg-RX-API-DMAC10.html)
MX (1) MX2020011294A (cg-RX-API-DMAC10.html)
NI (1) NI202000072A (cg-RX-API-DMAC10.html)
PE (1) PE20201202A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020551692A1 (cg-RX-API-DMAC10.html)
PL (1) PL3784664T3 (cg-RX-API-DMAC10.html)
PT (1) PT3784664T (cg-RX-API-DMAC10.html)
PY (1) PY1932509A (cg-RX-API-DMAC10.html)
RS (1) RS66650B1 (cg-RX-API-DMAC10.html)
RU (1) RU2762557C1 (cg-RX-API-DMAC10.html)
SG (1) SG11202009992VA (cg-RX-API-DMAC10.html)
SI (1) SI3784664T1 (cg-RX-API-DMAC10.html)
TW (1) TWI740135B (cg-RX-API-DMAC10.html)
UA (1) UA126177C2 (cg-RX-API-DMAC10.html)
UY (1) UY38196A (cg-RX-API-DMAC10.html)
WO (1) WO2019207463A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202006944B (cg-RX-API-DMAC10.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
CN118286225A (zh) * 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN110535628B (zh) 2019-08-29 2020-07-17 阿里巴巴集团控股有限公司 通过证书签发进行多方安全计算的方法及装置
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
PT4181920T (pt) 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
CN116322693A (zh) * 2020-08-13 2023-06-23 辉瑞公司 组合疗法
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
MX2023003054A (es) * 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.
CN112679522B (zh) * 2020-12-29 2023-02-14 南京正济医药研究有限公司 一种巴洛沙韦中间体的制备方法
WO2022149057A1 (en) * 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN120682245A (zh) 2021-02-03 2025-09-23 江苏恒瑞医药股份有限公司 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途
US20240269073A1 (en) * 2021-06-07 2024-08-15 Zerion Pharma ApS Co-amorphous forms for use in cancer therapy
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
AU2022400308B2 (en) * 2021-12-02 2026-02-12 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
EP4440575A1 (en) * 2021-12-02 2024-10-09 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
AU2023212957A1 (en) * 2022-01-25 2024-08-22 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
US12275738B2 (en) 2022-04-08 2025-04-15 Biolexis Therapeutics, Inc. CDK9 inhibitors
JP2025511975A (ja) * 2022-04-08 2025-04-16 バイオレクシス セラピューティクス,インコーポレイティド Cdk9阻害剤
IL316556A (en) * 2022-04-29 2024-12-01 Beigene Ltd 6-(Pyrimidine-4-yl)quinoline compounds are being developed as cyclin-dependent kinase inhibitors.
WO2023208172A1 (en) * 2022-04-29 2023-11-02 Beigene , Ltd. Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors
CN119630652A (zh) * 2022-07-29 2025-03-14 安锐生物医药公司 氨基杂芳基激酶抑制剂
JP2025533719A (ja) 2022-07-29 2025-10-09 ファイザー・インク がんの治療のためのkat6阻害剤を含む投与レジメン
WO2024027631A1 (zh) 2022-08-01 2024-02-08 江苏恒瑞医药股份有限公司 一种稠三环类衍生物的晶型及制备方法
KR20250054814A (ko) * 2022-09-05 2025-04-23 티와이케이 메디슨즈, 인코포레이티드 Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制(武汉)医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
WO2024220866A1 (en) * 2023-04-19 2024-10-24 Accutar Biotechnology Inc. Novel aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
JP2026519559A (ja) 2023-06-02 2026-06-16 ファイザー・インク エストロゲン受容体分解薬およびcdk4阻害剤の組合せ
CN120936609A (zh) * 2023-07-19 2025-11-11 浙江同源康医药股份有限公司 用作cdk2/4蛋白激酶抑制剂的化合物及其应用
TW202513069A (zh) 2023-07-21 2025-04-01 美商冰洲石生物科技公司 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物
EP4775575A1 (en) * 2023-09-05 2026-07-15 TYK Medicines, Inc. Compound used as cdk4 kinase inhibitor and use thereof
EP4791727A1 (en) * 2023-10-11 2026-08-19 Beone Medicines I GmbH Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors
WO2025104624A1 (en) 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol
WO2025141469A1 (en) 2023-12-26 2025-07-03 Pfizer Inc. Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide
WO2025157245A1 (en) * 2024-01-25 2025-07-31 Allorion Therapeutics Inc Aminoheteroaryl kinase inhibitors
WO2025183591A1 (ru) * 2024-02-29 2025-09-04 Федеральное государственное унитарное предприятие "Всероссийский научно-исследовательский институт автоматики им. Н.Л. Духова" (ФГУП "ВНИИА") Производные 2н-[1,4]оксазино- и 2h-[1, 4]тиазино[3,2-c]хинолин-3(4h)-онов в качестве ингибиторов атм и dna-pk киназ
TW202539674A (zh) * 2024-03-05 2025-10-16 大陸商浙江同源康醫藥股份有限公司 用作cdk4蛋白激酶抑制劑的化合物及其應用
WO2025202871A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202900A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
CN118440041B (zh) * 2024-07-02 2024-09-27 苏州凯瑞医药科技有限公司 一种手性4-氨基-3-羟基四氢吡喃的制备方法
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments
TW202611038A (zh) * 2024-09-04 2026-03-16 大陸商浙江同源康醫藥股份有限公司 用作cdk4蛋白激酶抑制劑的化合物及其應用
WO2026133192A1 (en) 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
CN105111191A (zh) 2015-07-21 2015-12-02 上海皓元生物医药科技有限公司 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途
WO2018013867A1 (en) 2016-07-13 2018-01-18 Marineau Jason J Inhibitors of cyclin dependnt kinase 7 (cdk7)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
GB0317127D0 (en) * 2003-07-22 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
BRPI0719122A2 (pt) * 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
WO2009110254A1 (ja) 2008-03-04 2009-09-11 日本電気株式会社 電界効果トランジスタ及びその製造方法
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
SG172282A1 (en) 2008-12-19 2011-07-28 Hoffmann La Roche Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
MX2012002641A (es) 2009-09-10 2012-03-14 Hoffmann La Roche Inhibidores de cinasa janus (jak).
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JO3300B1 (ar) * 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
WO2015058163A2 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
KR102379517B1 (ko) 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
WO2016014904A1 (en) 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
WO2016015604A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
MX385777B (es) 2014-12-24 2025-03-04 Lg Chemical Ltd Derivado de biarilo como agonista de gpr120.
WO2016192630A1 (zh) 2015-06-01 2016-12-08 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
AU2016283105C1 (en) * 2015-06-26 2023-02-02 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
CN105153119B (zh) * 2015-09-11 2019-01-01 广州必贝特医药技术有限公司 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用
CN106928216A (zh) 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
US10662186B2 (en) 2015-12-31 2020-05-26 Shanghai Pharmaceuticals Holding Co., Ltd. Substituted pyrimidines as cyclin-dependent kinase inhibitors
TWI736578B (zh) 2016-02-06 2021-08-21 大陸商上海複尚慧創醫藥研究有限公司 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
WO2019057123A1 (zh) 2017-09-20 2019-03-28 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN118286225A (zh) * 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
CN105111191A (zh) 2015-07-21 2015-12-02 上海皓元生物医药科技有限公司 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途
WO2018013867A1 (en) 2016-07-13 2018-01-18 Marineau Jason J Inhibitors of cyclin dependnt kinase 7 (cdk7)

Also Published As

Publication number Publication date
US20190330196A1 (en) 2019-10-31
EP3784664A1 (en) 2021-03-03
CN112313219B (zh) 2024-04-26
CA3098283A1 (en) 2019-10-31
US20220089580A1 (en) 2022-03-24
CR20200503A (es) 2020-12-17
GEP20227433B (en) 2022-10-25
AU2019259653B2 (en) 2023-01-19
ZA202006944B (en) 2023-07-26
US11220494B2 (en) 2022-01-11
ECSP20067394A (es) 2020-12-31
CA3098283C (en) 2023-05-23
NI202000072A (es) 2021-03-23
BR112020021689A2 (pt) 2021-01-26
CU20200070A7 (es) 2021-05-12
TW202000661A (zh) 2020-01-01
MX2020011294A (es) 2020-11-18
RU2021136543A (ru) 2021-12-16
RU2762557C1 (ru) 2021-12-21
FI3784664T3 (fi) 2025-04-09
DK3784664T3 (da) 2025-03-03
KR20230152182A (ko) 2023-11-02
JP7089061B2 (ja) 2022-06-21
WO2019207463A1 (en) 2019-10-31
RS66650B1 (sr) 2025-04-30
CN112313219A (zh) 2021-02-02
DOP2020000191A (es) 2021-02-28
LT3784664T (lt) 2025-03-25
KR102661053B1 (ko) 2024-04-26
AU2019259653A1 (en) 2020-10-29
PL3784664T3 (pl) 2025-05-12
IL278075B2 (en) 2023-05-01
US12378232B2 (en) 2025-08-05
HUE070823T2 (hu) 2025-07-28
KR20210002642A (ko) 2021-01-08
US20200354350A1 (en) 2020-11-12
PE20201202A1 (es) 2020-11-11
IL278075B1 (en) 2023-01-01
IL278075A (en) 2020-11-30
PH12020551692A1 (en) 2021-07-19
EP3784664B1 (en) 2025-02-19
JP2021522275A (ja) 2021-08-30
JP2022120096A (ja) 2022-08-17
CN118286225A (zh) 2024-07-05
SI3784664T1 (sl) 2025-05-30
PT3784664T (pt) 2025-04-23
HRP20250254T1 (hr) 2025-04-11
UA126177C2 (uk) 2022-08-25
MD3784664T2 (ro) 2025-06-30
BR112020021689B1 (pt) 2023-02-28
UY38196A (es) 2019-11-29
PY1932509A (es) 2020-10-02
SG11202009992VA (en) 2020-11-27
GEAP202215475A (en) 2022-07-11
ES3021205T3 (en) 2025-05-26
MA52360A (fr) 2021-03-03
CL2020002748A1 (es) 2021-02-12
MA52360B1 (fr) 2025-05-30
TWI740135B (zh) 2021-09-21
CO2020013149A2 (es) 2020-11-10
US10766884B2 (en) 2020-09-08

Similar Documents

Publication Publication Date Title
KR102661053B1 (ko) 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체
AU2023200842B2 (en) 3-carbonylamino-5-cyclopentyl-1H-pyrazole compounds having inhibitory activity on CDK2
US11834453B2 (en) Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
RU2790006C2 (ru) Производные 2-аминопиридина или 2-аминопиримидина в качестве циклинзависимых ингибиторов киназы
HK40046173A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
OA19876A (en) 2-Amino-Pyridine or 2-Amino-Pyrimidine derivatives as cyclin dependent kinase inhibitors.
HK40113584A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
EA042105B1 (ru) Производные 2-амино-пиримидина в качестве ингибиторов циклинзависимых киназ
EA046965B1 (ru) 3-карбониламино-5-циклопентил-1h-пиразольные соединения, обладающие ингибирующей активностью в отношении cdk2
HK40046173B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601